Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Gene Technology, ExonHit Therapeutics, Asper Biotech

Oxford Gene Technology this week launched a microRNA-profiling service. The service enables customers to submit samples for analysis on custom-designed arrays using up-to-date miRNA array content and receive data back within days, OGT said.
In developing the service, OGT has co-funded the design of novel miRNA microarrays with the Molecular Phenotyping to Accelerate Genomic Epidemiology project, a pan-European consortium coordinated by Oxford University that focuses on diabetes and vascular disease.
According to OGT, researchers will use its miRNA microarrays to measure the expression levels of mature miRNA and miRNA star sequences in biomarker-discovery samples.

ExonHit Therapeutics last week launched its Rat SpliceArray for use in disease modeling and toxicogenomic applications by the basic and pre-clinical research communities.
The Rat SpliceArray monitors over 23,000 genes and uses more that 200,000 exon-body and 180,000 splice-junction regions. The designs, manufactured on the Agilent Technologies and Affymetrix microarray platforms, expand ExonHit’s product offering and enables researchers to leverage alternative splicing discovery in the rat model system.

Asper Biotech recently updated its Ashkenazi Jewish diseases test to include 8 new mutations.
The new version covers 77 mutations from 22 different genes related to cystic fibrosis, Tay Sachs, Bloom -, Canavan -, Niemann-Pick A syndrome, familian dysautonomia, torsion dystonia, mucolipidosis IV, Fanconi anemia, factor XI deficiency, glycogen storage disease, maple syrup urine disease, nonsyndromic sensorineural hearing loss, familial mediterranean fever, alpha 1-anti-trypsin deficiency, nemaline myopathy, Usher syndrome type 1F, familial hyperinsulinemia, familial hypercholesterolemia, and Gaucher disease and lipoamide dehydrogenase deficiency.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.